Development of Tizanidine HCl transdermal patches: In-vitro and Ex-vivo characterization
Abstract
The purpose of this work was to design and evaluate matrix type transdermal patches of Tizanidine hydrochloride using Hypromellose (HPMC E15) as polymer, dibutyl phthalate as plasticizer and citral as permeation enhancer. The DSC and FTIR results showed the compatibility of the excipients with the drug. These transdermal drug delivery systems were characterized for their thickness, folding endurance, content uniformity, tensile strength and in-vitro release studies of the drug from the polymeric matrix. In-vitro release studies and ex-vivo permeation were carried out with modified Franz diffusion cell using pH 5.8 & pH 7.4 phosphate buffers as receptor medium and it showed controlled release of drug. The results suggest that the formulation of TIZ may be useful in the development of a therapeutic system to deliver TIZ across the skin for a prolonged period, i.e. 24 hr.
Keywords: Tizanidine Hydrochloride, Transdermal patch, HPMC E15, in-vitro & ex-vivo.
Downloads
References
2. Arun Raj R, Formulation Evaluation And In Vitro Permeation Studies Of Transdermal Nifedipine From Matrix Type Patches, International Journal of Pharmacy and Pharmaceutical Sciences, 2014; 6(1):185-188.
3. Asha Das, Abdul Baquee Ahmed, Formulation And Evaluation Of Transdermal Patch Of Indomethacin Containing Patchouli Oil As Natural Penetration Enhancer, Asian Journal of Pharmaceutical and Clinical Research,2017; 10(11):320-325.
4. Donbrow M, Samuelov Y, J. Pharm. Pharmacol, 1980; 32:463-470.
5. Shingade G, Review on: recent trend on transdermal drug delivery system. Journal of Drug Delivery and Therapeutics, 2012; 2(1):66-75.
6. Higuchi T, J. Pharm. Sci, 1963; 52(12):1145-1149.
7. Jun Chen, Qiu-Dong Jiang, Ya-Ping Chai, Hui Zhang, Pei Peng and Xi-Xiong Yang, Natural Terpenes as Penetration Enhancers for Transdermal Drug Delivery, Molecules J, 2016; 21:1709,1-22.
8. Rahman SAU, & Sharma N, Formulation and evaluation of matrix transdermal patches of glibenclamide. Journal of Drug Delivery and Therapeutics, 2018; 8(5-s):366-371.
9. Kusum Devi V, Saisivam S, Maria G.R, Deepti P.U, Drug Dev. Ind. Pharm, 2003; 29:495-503.
10. Nuntakan Suwanpiodokkul, Phensri Thongnopnua, Kaisri Umprayan, AAPS Pharm. SciTech, 2004; 5(48):1-7.
11. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Scihonen T.M, Urtti A, Int. J. Pharm, 2003; 254:99-107.
12. Ramesh Gannu, Vamshi Vishnu Y, Kishan V and Madhusudan Rao Y; Development of Nitrendipine Transdermal Patches: In vitro and Ex vivo Characterization, Current Drug Delivery, 2007; 4:69-76.
13. Robinson J.R, Lee V.H, 1987, Controlled Drug Delivery: Fundamentals and Applications, Marcel Dekker, New York, 523-552.
14. Wagner J.G, J. Pharm. Sci, 1969; 58:1253-1257.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.